Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in pulmonary arterial hypertension and right heart failure

Back

ESC Premium Access

Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in pulmonary arterial hypertension and right heart failure

Session: Pulmonary hypertension: progress in management, impact on outcomes

Topic: Pharmacotherapy

Speaker: Miss S. Andersen (Aarhus, DK)

Event: ESC Congress 2018

Congress Presentation

About the speaker

Miss Stine Andersen

Aarhus University Hospital, Aarhus (Denmark)

0 follower

9 more presentations in this session

Fast screening breath analysis for diagnostics of pulmonary hypertension.

Speaker: Assistant Professor A. Swinarew (Katowice, PL)

Phenomapping to detect non-invasively patients with combined postcapillary pulmonary hypertension

Speaker: Doctor O. Raitiere (Rouen, FR)

Impact of comorbidity on outcome in CTD-associated pulmonary arterial hypertension: data from the Swedish Pulmonary Arterial Hypertension Registry

Speaker: Doctor C. Hjalmarsson (Gothenburg, SE)

Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension

Speaker: Professor N. Galie (Bologna, IT)

Improved ten-year survival of systemic sclerosis-associated pulmonary arterial hypertension in the contemporary treatment era: a single centre retrospective study of 451 patients.

Speaker: Doctor H. Fayed (London, GB)

Access the full session

Pulmonary hypertension: progress in management, impact on outcomes

Speakers: Miss S. Andersen, Assistant Professor A. Swinarew, Doctor O. Raitiere, Doctor C. Hjalmarsson, Professor N. Galie...

Access

About the event

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

Congress

Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in pulmonary arterial hypertension and right heart failure

About the speaker

Miss Stine Andersen

9 more presentations in this session

Fast screening breath analysis for diagnostics of pulmonary hypertension.

Phenomapping to detect non-invasively patients with combined postcapillary pulmonary hypertension

Impact of comorbidity on outcome in CTD-associated pulmonary arterial hypertension: data from the Swedish Pulmonary Arterial Hypertension Registry

Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension

Improved ten-year survival of systemic sclerosis-associated pulmonary arterial hypertension in the contemporary treatment era: a single centre retrospective study of 451 patients.

Access the full session

Pulmonary hypertension: progress in management, impact on outcomes

About the event

ESC Congress 2018

ESC 365 is supported by